New Schizophrenia Drug Will Likely Have Familiar Coverage

Earlier this month, the FDA approved a drug that the manufacturer touts as “the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults.” Drug benefits experts say it could be a good option for patients who have previously been on extended-release drugs for the schizophrenia — with careful monitoring — and will likely be covered similar to existing long-acting treatments.

The drug is called Invega Hafyera (six-month paliperidone palmitate), a product produced by Janssen Pharmaceuticals, Inc., a Johnson & Johnson unit. It received FDA clearance on Sept. 1 after a randomized, double-blind, non-inferiority Phase III global study that enrolled 702 adults living with schizophrenia from 20 countries, which found that 92.5% of patients treated with Invega Hafyera were relapse-free at 12 months.

© 2023 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

businessman-viewing-news-update-journalism-headline-on-a-laptop
November 22

News Briefs: CDC Makes More RSV Immunizations Available to Infants

READ MORE
dna-strand
November 22

Papers Delve Into Payment Options for Gene Therapies

READ MORE
pills
November 22

A Closer Look at the Medicare Part D Landscape

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today